Avidity Biosciences (RNA) Accumulated Depreciation & Amortization (2019 - 2025)
Avidity Biosciences (RNA) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $11.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 47.32% year-over-year to $11.8 million, compared with a TTM value of $11.8 million through Dec 2025, up 47.32%, and an annual FY2025 reading of $11.8 million, up 47.32% over the prior year.
- Accumulated Depreciation & Amortization was $11.8 million for Q4 2025 at Avidity Biosciences, up from $9.6 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $11.8 million in Q4 2025 and bottomed at $1.7 million in Q4 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $5.9 million, with a median of $5.9 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization dropped 12.43% in 2021, then skyrocketed 80.03% in 2022.
- Year by year, Accumulated Depreciation & Amortization stood at $1.7 million in 2021, then skyrocketed by 80.03% to $3.1 million in 2022, then skyrocketed by 67.34% to $5.2 million in 2023, then soared by 53.17% to $8.0 million in 2024, then surged by 47.32% to $11.8 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for RNA at $11.8 million in Q4 2025, $9.6 million in Q2 2025, and $8.0 million in Q4 2024.